Emergent Biosolutions wins fresh U.S. government agreement and boosts international orders

Emergent Biosolutions wins fresh U.S. government agreement and boosts international orders
Emergent wins U.S. smallpox deal

Emergent Biosolutions has announced the award of a new contract with the U.S. government, focusing on the supply of smallpox medical countermeasures.

The company also revealed it has received new orders from an international partner, further expanding the reach of its smallpox preparedness products. As governments around the world look to strengthen their public health security, Emergent Biosolutions continues to play an active role in infectious disease countermeasure markets. Further details on the scope, value, and timeline of these agreements were not disclosed in the announcement.

Emergent Biosolutions recently announced multiple new agreements with Canadian government agencies to expand support for public health and defence, according to a previous disclosure. The company has also launched new carrying cases for its NARCAN Nasal Spray to increase access to overdose response products, as reported earlier. These efforts have broadened Emergent’s presence in both infectious disease prevention and overdose intervention markets.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.